291 related articles for article (PubMed ID: 11922901)
21. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
[TBL] [Abstract][Full Text] [Related]
22. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment.
Maack C; Kartes T; Kilter H; Schäfers HJ; Nickenig G; Böhm M; Laufs U
Circulation; 2003 Sep; 108(13):1567-74. PubMed ID: 12963641
[TBL] [Abstract][Full Text] [Related]
23. Rac1 and RhoA differentially regulate angiotensinogen gene expression in stretched cardiac fibroblasts.
Verma SK; Lal H; Golden HB; Gerilechaogetu F; Smith M; Guleria RS; Foster DM; Lu G; Dostal DE
Cardiovasc Res; 2011 Apr; 90(1):88-96. PubMed ID: 21131638
[TBL] [Abstract][Full Text] [Related]
24. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes.
Blanco-Colio LM; Muñoz-García B; Martín-Ventura JL; Lorz C; Díaz C; Hernández G; Egido J
Circulation; 2003 Sep; 108(12):1506-13. PubMed ID: 12952848
[TBL] [Abstract][Full Text] [Related]
25. Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy.
Custodis F; Eberl M; Kilter H; Böhm M; Laufs U
Cardiovasc Res; 2006 Jul; 71(2):342-51. PubMed ID: 16698001
[TBL] [Abstract][Full Text] [Related]
26. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.
Park HJ; Kong D; Iruela-Arispe L; Begley U; Tang D; Galper JB
Circ Res; 2002 Jul; 91(2):143-50. PubMed ID: 12142347
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy.
Ye Y; Mou Y; Bai B; Li L; Chen GP; Hu SJ
Int J Biochem Cell Biol; 2010 Dec; 42(12):2056-64. PubMed ID: 20884373
[TBL] [Abstract][Full Text] [Related]
28. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury.
Mason JC; Ahmed Z; Mankoff R; Lidington EA; Ahmad S; Bhatia V; Kinderlerer A; Randi AM; Haskard DO
Circ Res; 2002 Oct; 91(8):696-703. PubMed ID: 12386146
[TBL] [Abstract][Full Text] [Related]
29. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).
Eberlein M; Heusinger-Ribeiro J; Goppelt-Struebe M
Br J Pharmacol; 2001 Aug; 133(7):1172-80. PubMed ID: 11487529
[TBL] [Abstract][Full Text] [Related]
30. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation.
Adam O; Lavall D; Theobald K; Hohl M; Grube M; Ameling S; Sussman MA; Rosenkranz S; Kroemer HK; Schäfers HJ; Böhm M; Laufs U
J Am Coll Cardiol; 2010 Feb; 55(5):469-80. PubMed ID: 20117462
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of the inhibitory effect of atorvastatin on leptin expression induced by angiotensin II in cultured human coronary artery smooth muscle cells.
Shyu KG; Chen SC; Wang BW; Cheng WP; Hung HF
Clin Sci (Lond); 2012 Jan; 122(1):33-42. PubMed ID: 21806545
[TBL] [Abstract][Full Text] [Related]
32. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells.
Li M; Li Z; Sun X
Eur J Pharmacol; 2008 Sep; 591(1-3):219-23. PubMed ID: 18619957
[TBL] [Abstract][Full Text] [Related]
33. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257
[TBL] [Abstract][Full Text] [Related]
34. Cellular antioxidant effects of atorvastatin in vitro and in vivo.
Wassmann S; Laufs U; Müller K; Konkol C; Ahlbory K; Bäumer AT; Linz W; Böhm M; Nickenig G
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):300-5. PubMed ID: 11834532
[TBL] [Abstract][Full Text] [Related]
35. Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways.
Sah VP; Hoshijima M; Chien KR; Brown JH
J Biol Chem; 1996 Dec; 271(49):31185-90. PubMed ID: 8940118
[TBL] [Abstract][Full Text] [Related]
36. SmgGDS as a Crucial Mediator of the Inhibitory Effects of Statins on Cardiac Hypertrophy and Fibrosis: Novel Mechanism of the Pleiotropic Effects of Statins.
Kudo S; Satoh K; Nogi M; Suzuki K; Sunamura S; Omura J; Kikuchi N; Kurosawa R; Satoh T; Minami T; Ikeda S; Miyata S; Shimokawa H
Hypertension; 2016 May; 67(5):878-89. PubMed ID: 26975711
[TBL] [Abstract][Full Text] [Related]
37. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism.
Ito M; Adachi T; Pimentel DR; Ido Y; Colucci WS
Circulation; 2004 Jul; 110(4):412-8. PubMed ID: 15262848
[TBL] [Abstract][Full Text] [Related]
38. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Oi S; Haneda T; Osaki J; Kashiwagi Y; Nakamura Y; Kawabe J; Kikuchi K
Eur J Pharmacol; 1999 Jul; 376(1-2):139-48. PubMed ID: 10440099
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of RhoA or Rac1? Mechanism of cholesterol-independent beneficial effects of statins.
Rikitake Y; Hirata K
Circ J; 2009 Feb; 73(2):231-2. PubMed ID: 19164861
[No Abstract] [Full Text] [Related]
40. MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: a new mechanism for antihypertrophic intervention.
Tu Y; Wan L; Bu L; Zhao D; Dong D; Huang T; Cheng Z; Shen B
Cell Physiol Biochem; 2013; 31(6):997-1008. PubMed ID: 23860036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
